Alexander Bastian speaks about the need for a sustainable model of pricing as related to cancer treatments and drug development. He talks about indication-based pricing or tumor-based pricing—says that is compelling, but not necessarily possible in the US.
Video Categories: PricingGrant Lawless discusses the changing landscape of pricing personalized medicines
Video Categories: PricingJayson Slotnik discusses the cost structure of diagnostics and pharmaceuticals in personalized medicine
Video Categories: PricingRandy Vogenberg discusses the complexities of developing pricing for personalized medicine products
Video Categories: PricingMatthew Palmgren discusses the benefits of personalized medicines
Video Categories: Pricing